

PERFORMANCE IN INITIATING CLINICAL RESEARCH (Q1, 2014/15)

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met?	Reason for not meeting benchmark
13/NW/0363	A Multi-Centre Openlabel Extension (OLE) Study to Assess the Long term Safety and Efficacy of AMG 145	14/10/2013	05/12/2013	Yes	Benchmark met
13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 infection	22/10/2013	29/10/2013	Yes	Benchmark met
13/SC/0208	A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME TRAP and also RTS,S/A01B alone	25/08/2013	03/09/2013	Yes	Benchmark met
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Treatment with Peginterferon Alfa-2a and Ribavirin	29/08/2013	16/09/2013	Yes	Benchmark met
13/LO/0830	Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naive genotypes 1, 2, 3 or 4 in subjects co-infected with HIV	30/10/2013	19/11/2013	Yes	Benchmark met
13/LO/0849	Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes	23/10/2013	22/11/2013	Yes	Benchmark met
12/EE/0400	GS-US-334-0109: An open label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977	10/07/2013	13/08/2013	Yes	Benchmark met
13/LO/0206	A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b who are Treatment Naive or Prior Replacers to Alfa/RBV Therapy	08/07/2013	12/08/2013	Yes	Benchmark met
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	22/10/2013	27/11/2013	Yes	Benchmark met
1/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301	07/01/2014	12/02/2014	Yes	Benchmark met
13/EE/0102	PIVOT Neurocognitive function sub-study	03/07/2013	15/08/2013	Yes	Benchmark met
13/LO/1758	A Phase III, Randomized, Placebo-Controlled, Parallel Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimers Disease (Prodromal AD)	13/03/2014	25/04/2014	Yes	Benchmark met
13/EE/0276	A Phase 3B Randomized, Open-Label Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	17/09/2013	31/10/2013	Yes	Benchmark met
13/EN/0348	Safety and Efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % with ocular surface intolerance	10/03/2014	07/05/2014	Yes	Benchmark met
13/YH/0281	Evaluation of [18F]FETβAGTOCA for the imaging of NETs	10/03/2014	16/05/2014	Yes	Benchmark met
13/LO/1725	Prospective, multi-center, double blind, ranodmised study to test the safety of deferral of stenting in a physiological non-significant lesions in a clinical population of intermediate senoses using iFR and FFR	09/01/2014	13/01/2014	Yes	Benchmark met
13/LO/0365	An efficacy and mechanism evaluation study for Levosimendan for the prevention of accute organ dysfunction in sepsis (LeoPARDS)	10/01/2014	20/01/2014	Yes	Benchmark met
13/LO/1340	Defining a gold standard for ischaemia: Effects of interventional revascularisation versus optimum medical therapy on exercise capacity in patients with stable coronary artery disease	29/11/2013	11/12/2013	Yes	Benchmark met

13/YH/0275	Revitive for the treatment of venous insufficiency	28/01/2014	20/02/2014	Yes	Benchmark met
13/LO/1150	The role of left atrial ganglionated plexi sites that trigger pulmonary vein ectopy in the pathogenesis of paroxysmal atrial fibrillation	06/11/2013	02/12/2013	Yes	Benchmark met
13/LO/1375	A randomised controlled trial to evaluate the impact of psychological support intervention after chemotherapy for women with ovarian cancer	30/10/2013	28/11/2013	Yes	Benchmark met
14/YH/0034	IciCLL: Assessment of the Mechanism of Action of Ibrutinib (PCI32765) in Bcell Receptor Pathway Inhibition in CLL	29/05/2014	15/07/2014	Yes	Benchmark met
11/SS/0092	Trial of BIBW 2992 in suspected mutant EGFR lung cancer patients unfit for chemotherapy	11/09/2013	15/10/2013	Yes	Benchmark met
12/LO/1078	A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma patients.	16/05/2014	19/06/2014	Yes	Benchmark met
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	17/10/2013	27/11/2013	Yes	Benchmark met
14/LO/0057	iPre-Pare: Intelligent Pre-operative Planning for Adverse event Reduction during Endovascular and vascular surgery.	17/01/2014	27/02/2014	Yes	Benchmark met
13/LO/1332	A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment	25/02/2014	14/04/2014	Yes	Benchmark met
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Treatment with Erlotinib	11/12/2013	29/01/2014	Yes	Benchmark met
13/LO/1352	A phase II, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280a (anti-PD-L1 antibody) compared with docetaxel in patients with no-small cell lung cancer after platinum failure	23/10/2013	16/12/2013	Yes	Benchmark met
13/WA/0178	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (protocol ID EMR200592-001)	14/08/2013	10/10/2013	Yes	Benchmark met
12/WM/0087	Phase I/II Randomised Trial of 5-Azacididine versus 5-Azacididine in combination with Vorinostat in patients with Relapsed Acute Myeloid Leukaemic Ineligible for Intensive Chemotherapy (RAVVA)	15/07/2013	11/09/2013	Yes	Benchmark met
13/LO/1305	Systematic Assessment of Pulmonary Artery Haedodynamics using Wave Intensity Analysis	10/10/2013	12/12/2013	Yes	Benchmark met
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	29/08/2013	31/10/2013	Yes	Benchmark met
12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease	03/07/2013	04/09/2013	Yes	Benchmark met
13/LO/1091	Non-invasive Pressure-Volume Analysis (NIPVA): extending comprehensive left ventricular pump function assessment to more patients and settings	13/08/2013	17/10/2013	Yes	Benchmark met
11/YH/0006	Magnetic Resonance Imaging to Enhance the Diagnosis of Foetal Developmental Brain Abnormalities in Utero	06/01/2014	14/01/2014	Yes	Benchmark met
14/SC/0132	A phase I, open label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy termination.	13/05/2014	30/06/2014	Yes	Benchmark met
13/LO/1677	Continenace Across Continents to Upend Stigma and Dependency	10/02/2014	31/03/2014	Yes	Benchmark met
13/WM/0231	Safety of Nasal Influenza Immunisation in Egg Allergic Children The SNIFFLE study	20/08/2013	17/10/2013	Yes	Benchmark met
14/LO/0302	A UK single centre study on the preoperative characterisation of ovarian tumours and conservative management of benign looking adnexal masses	21/03/2014	21/05/2014	Yes	Benchmark met

14/SC/0037	A phase III, randomised, double-blind, placebo-controlled, parallel group, multicentre efficacy and safety study of gantenerumab in subjects with mild Alzheimers Disease	12/05/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
12/LO/1889	Open-label, single arm extension study to the double-blind, randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis	23/04/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
14/SC/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia	06/06/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
13/LO/1557	A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcutaneous Administrations of Somatuline® (lanreotide) Autogel® to treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET).	13/05/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
12/SS/0109	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches	28/04/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer	24/06/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
13/HY/0424	Randomised trial of rapid outpatient rehydration versus hospital admission for management of hyperemesis gravidarum	29/05/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
14/LO/0130	Temperature Controlled Laminar Airflow (TLA) treatment in children with severe atopic eczema- Prospective Pilot Study	23/04/2014	First patient not yet recruited		Benchmark (70 days from VRA) not yet elapsed.
12/YH/0236	A multi-centre randomised controlled trial comparing rubber band ligation with haemorrhoidal artery ligation in the management of symptomatic second and third degree haemorrhoids	08/08/2013	19/11/2013	No	Contracting delays
13/LO/0181	Optimisation and Individualisation of HeartSparing Breast Radiotherpay Techniques (The Heart Spare Study) : stage II	06/01/2014	23/04/2014	No	Contracting delays
13/lo/1816	Intraocular Pressure And Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost)in patients with Ocular hypertension or Glaucoma: A Randomised, single masked, 3 month cross-over, Investigator led, European multicentre Trial (SPORT).	11/12/2013	15/05/2014	No	Contracting delays
13/SW/0199	A randomised clinical trial to compare early versus delayed endovenous treatment of superficial venous reflux in patients with chronic venous ulceration	01/10/2013	20/12/2013	No	No patients consented
10/H0405/29	Fistula-In-Ano Trial to compare Surgisis anal fistula plug versus surgeon's preference for transsphincteric fistula-in-ano	14/11/2013	04/02/2014	No	No patients consented
13/SC/0368	Comparison of ultra low dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease	08/11/2013	18/03/2014	No	No patients consented
12/LO/1762	Left ventricular MultiSpot Pacing for CRT (i-Spot)	22/05/2013	04/02/2014	No	No patients seen
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	18/06/2013	12/11/2013	No	No patients seen; Issues with scanner capability
13/LO/0882	Slow wave sleep and daytime functioning in chronic fatigue syndrome: effects of sodium oxybate	27/02/2014	19/05/2014	No	No patients seen; No patients consented
13/LO/1302	A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women	01/11/2013	12/02/2014	No	No patients seen; No patients consented
11/LO/1904	A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists	19/08/2013	06/01/2014	No	No patients seen; No patients consented
13/EM/0374	A doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)	24/12/2013	13/03/2014	No	No patients seen; No patients consented
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	11/09/2013	15/01/2014	No	No patients seen; Strict study eligibility criteria

14/NW/0300	A comparative study of two dressings for central venous catheters	18/02/2014	21/05/2014	No	Permissions delayed or denied
13/SW/0124	A performance evaluation study of UROSENSE MCM5-ELISA for the detection of prostate cancer in patients with known disease and in those presenting with raised serum prostate-specific antigen and/or abnormal prostate gland morphology	16/07/2013	09/10/2013	No	Permissions delayed or denied
13/SC/0311	A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP201 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma	07/08/2013	30/01/2014	No	Permissions delayed or denied
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	13/06/2013	30/09/2013	No	Permissions delayed or denied; Rare disease study
13/NW0697	PISARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	12/12/2013	06/05/2014	No	Permissions delayed or denied; Contracting delays
13/NW/0265	A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy (De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia)	18/09/2013	17/03/2014	No	Permissions delayed or denied; No patients consented; Contracting delays
14/LO/0067	The control of brain networks after traumatic brain injury: a neuroimaging and neuropsychological study of dopamine and cognition	28/04/2014	08/07/2014	No	Permissions delayed or denied; Radiopharmaceutical supply delays
13/YH/0117	Multi-Channel Near Infrared Spectroscopy to Detect Spreading Depolarisations in Brain Injured Patients	01/07/2013	03/10/2013	No	Permissions delayed or denied; Software update required for scanner
14/SC/0038	PET imaging substudy associated with a phase III randomized, double-blind, placebo-controlled, parallel group, multicentre efficacy and safety study of gantenerumab in patients with mild Alzheimer's Disease	14/01/2014	22/07/2014	No	Permissions delayed or denied; Sponsor delays
11/H0606/1	Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma? A randomised phase III trial	08/05/2013	13/03/2014	No	Permissions delayed or denied; Sponsor delays; Rare disease study
13/LO/0740	A randomized, multicenter, double blind phase 3 study of PD 0332991 (oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2 (-) breast cancer who have not received any prior systemic anti cancer treatment for advanced disease	29/11/2013	12/02/2014	No	Permissions delayed or denied; Sponsor delays; Contracting delays
13/LO/1916	Reproduceability of the 11C-PBR28 PET signal	11/12/2013	03/07/2014	No	Permissions delayed or denied; Staff availability issues
13/LO/0699	Evaluating the effects of the novel GLP-1 analogue, liraglutide, in patients with Alzheimers disease (ELAD Study)	01/10/2013	20/01/2014	No	Permissions delayed or denied; Staff availability issues;
12/WA/0345	A randomised Phase II study of two preoperative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer	26/03/2013	06/11/2013	No	Permissions delayed or denied; Staff availability issues; Contracting delays; Rare disease study
13/LO/1011	Molecular imaging coupled with advanced image processing for response assessment to transcatheter arterial chemoembolisation in patients with HCC	30/07/2013	15/10/2013	No	Rare disease study
11/WS/0039	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	08/08/2013	23/10/2013	No	Rare disease study
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	31/10/2013	21/01/2014	No	Rare disease study
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	02/10/2013	12/02/2014	No	Rare disease study
13/LO/1813	Effect of minocycline on chronic neuroinflammation following traumatic brain injury (TBI)	18/03/2014	11/07/2014	No	Sponsor delays
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	25/09/2013	27/01/2014	No	Sponsor delays
12/NE/0315	Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE)	25/03/2013	15/08/2013	No	Sponsor delays; Contracting delays
13/LO/1380	I-Scan for the detection and characterisation of mucosal lesions a randomised controlled study	12/11/2013	11/03/2014	No	Sponsor delays; Contracting delays
13/WM/0017	Anticoagulation Therapy in SELECTd Cancer Patients at Risk of Recurrence of Venous Thromboembolism	14/05/2013	17/01/2014	No	Sponsor delays; Contracting delays
12/LO/1133	A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG)	23/07/2013	11/02/2014	No	Sponsor delays; Contracting delays; Rare disease study

10/MRE/09/29	A Phase I/II trial of isotoxic accelerated radiotherapy in the treatment of patients with non-small cell lung cancer (I-START)	20/06/2013	14/01/2014	No	Sponsor delays; Contracting delays; Rare disease study
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis	18/06/2013	15/04/2014	No	Sponsor delays; IMP supply issues
08/H1102/112	Safety and efficacy of intensive versus guideline antiplatelet therapy in high risk patients with recent ischaemic stroke or transient ischaemic attack: a randomised controlled trial	18/11/2013	11/07/2014	No	Sponsor delays; No patients consented
12/EM/0369	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage TICH2	30/07/2013	03/03/2014	No	Sponsor delays; No patients consented; Contracting delays
11/LO/1776	Urinary Proteomics for HIGH Risk pregnancies (UP HIGH R) - PEACHES	20/06/2013	10/12/2013	No	Sponsor delays; Staff availability issues; Contracting delays
12/EE/0274	Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial	22/02/2014	23/06/2014	No	Staff availability issues
13/LO/0683	Predicting Delirium After Neck of Femur Fracture	02/10/2013	01/07/2014	No	Staff availability issues
13/NW/0634	A Phase 1b, multicenter, openlabel, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	19/11/2013	15/05/2014	No	Staff availability issues
13/LO/0420	The safety and immunogenicity of a potential HIV vaccine	04/09/2013	19/11/2013	No	Suspended by sponsor
13/EE/0214	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	24/03/2014	10/06/2014	No	US FDA regulations
12/SW/0378	Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	14/04/2014	First patient not recruited		Bereavement within study team
12/WM/0341	To examine the effect of cholesterol-lowering on carotid plaque burden and stability, cerebrovascular disease and cognitive function in patients recruited to fourier	01/08/2013	First patient not recruited		Closed by sponsor
13/LO/1290	A Followup Study to Assess Resistance and Durability of Response to AbbVie DirectActing Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	22/10/2013	First patient not recruited		Closed by sponsor
13/SC/0249	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with compensated cirrhosis secondary to non alcoholic steatohepatitis (NASH) GS-US-321-0106 (cirrhosis due to NASH))	29/07/2013	First patient not recruited		Closed by sponsor
13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like molecular 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	24/07/2013	First patient not recruited		Closed by sponsor
13/LO/0097	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with advanced liver fibrosis but not cirrhosis secondary to non alcoholic steatohepatitis (NASH GS-US-321-0105 - (GS-6624 for Advanced Liver Fibrosis)	24/07/2013	First patient not recruited		Closed by sponsor
12/LO/0923	A Phase 3, randomized, doubleblind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castrationresistant prostate cancer	23/05/2014	First patient not recruited		Closed by sponsor
12/LO/0980	Protocol EC-FV-06: A randomized double-blind phase 3 trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/doxil®/caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer	20/03/2014	First patient not recruited		Closed by sponsor
13/EE/0365	Investigation of newly developed 1- and 2-piece convex ostomy products in subjects with ileostomy	11/12/2013	First patient not recruited		Closed by sponsor
13/SC/0291	An open label, phase I study to evaluate the impact of severe hepatic impairment on the pharmacokinetics and safety of vemurafenib in BRAFV600 mutation positive cancer patients	18/11/2013	First patient not recruited		Closed by sponsor
12/EE/0231	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone	07/04/2014	First patient not recruited		Closed by sponsor; Rare disease study

12/NW/0802	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)	04/11/2013	First patient not recruited		Closed by sponsor; Sponsor delays
13/EE/0429	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies	07/01/2014	First patient not recruited		Contracting delays
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE)	24/09/2013	First patient not recruited		No patients consented
13/NE/0125	PRESTO Neo.1.C/E	29/08/2013	First patient not recruited		No patients consented
12/LO/0155	Randomised controlled trial of tailored home exercise versus advice and usual care for disability in people with immune mediated neuropathy	16/12/2013	First patient not recruited		No patients consented; Rare disease study
13/LO/1081	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	31/01/2014	First patient not recruited		No patients consented; Rare disease study
14/LO/0026	The long-term safety and effect of renal denervation	17/02/2014	First patient not recruited		No patients seen
13/LO/1844	Electrical stimulation in diabetic peripheral neuropathy	15/10/2013	First patient not recruited		No patients seen; Contracting delays
13/NW/0464	A Placebo-Controlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure	03/10/2013	First patient not recruited		No patients seen; No patients consented
13/LO/1639	Patient matched osteotomy to correct angular deformities in knee arthrosis	02/12/2013	First patient not recruited		Permissions delayed or denied
12/LO/1158	Bevacizumab And Combination Chemotherapy in rectal cancer Until Surgery: A Phase II, Multicentre, Openlabel, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined HighRisk Cancer of the Rectum	27/11/2013	First patient not recruited		Permissions delayed or denied; Rare disease study
13/YH/0229	GO2: Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer.	08/10/2013	First patient not recruited		Permissions delayed or denied; Rare disease study
13/LO/1182	Pilot study to evaluate the feasibility of functional MRI in metastatic renal cell carcinoma (mRCC) with test-retest repeatability and early response assessment	01/08/2013	First patient not recruited		Permissions delayed or denied; No patients consented
13/LO/1279	To evaluate the role of LifeNote in rates of medicine adherence and also its acceptability in patients at high multifactorial risk of developing cardiovascular disease attending the MyAction Westminster programme	20/08/2013	First patient not recruited		Permissions delayed or denied; Staff availability issues
13/SC/0111	FOCUS4 Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme	30/09/2013	First patient not recruited		Permissions delayed or denied; Staff availability issues; Rare disease study
13/SC/0589	Optimisation of Onpulse technology for patients with post surgical or vascular oedema	08/01/2014	First patient not recruited		Permissions delayed or denied; Staff availability issues; Contracting delays
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	18/08/2013	First patient not recruited		Rare disease study
13/LO/1296	Pilot study to evaluate diffusion weighted MRI (DWMRI) with Intravoxel Incoherent Motion (IVIM) and arterial spin labelling (ASL) at 3T in metastatic or locally advanced pancreatic neuroendocrine tumours (pNET): test-retest and response assessment	06/02/2014	First patient not recruited		Rare disease study
11/NE/0214	Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms	21/08/2013	First patient not recruited		Rare disease study
13/NW/0702	A Phase III, randomised, multicentre, open label study of active symptom control (ASC) alone or ASC with oxaliplatin/SFU chemotherapy for patients with locally advanced/metastatic biliary tract cancers previously treated with cisplatin / gemcitabine chemotherapy	28/03/2014	First patient not recruited		Rare disease study
13/LO/0501	A phase 2, randomized, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of maribavir versus valganciclovir for treatment of CMV infections in transplant recipients who do not have CMV organ disease	06/09/2013	First patient not recruited		Sponsor delays
13/LO/1050	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	02/12/2013	First patient not recruited		Sponsor delays; Contracting delays

13/nw/0583	A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate Glycemic Control with Diet and Exercise	17/12/2013	First patient not recruited		Sponsor delays; CRO delays
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	02/08/2013	First patient not recruited		Sponsor delays; No patients consented; Contracting delays
13/YH/0174	A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis	25/10/2013	First patient not recruited		Sponsor delays; Staff availability issues; Contracting delays
13/SW/0192	European multicenter registry using hybrid staged operationg room and interventional catheter ablation techniques to treat chronic atrial fibrillation.	18/03/2014	First patient not recruited		Staff availability issues
12/LO/1636	Validation of Sensium wireless device in a paediatric population	07/08/2013	First patient not recruited		Staff availability issues
12/LO/1188	A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone	01/08/2013	First patient not recruited		Suspended by sponsor; Closed by sponsor